[ARVO2012]IVAN研究1年结果
国际眼科时讯版权所有，谢绝任何形式转载，侵犯版权者必予法律追究。
内容概要： One year after randomization, the comparison between bevacizumab andranibizumab was inconclusive (bevacizumab minus ranibizumab -1.99 letters, 95%confidence interval (CI) -4.04 to 0.06). Discontinuous treatment was equivalent to continuoustreatment (discontinuous minus continuous -0.35 letters, 95% CI -2.40 to 1.70).